Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 20/20 | 1.00 |
| ▸ | MMP2 | P08253 | 17/20 | 1.00 |
| ▸ | MMP1 | P03956 | 9/20 | 1.00 |
| ▸ | MMP3 | P08254 | 1/20 | 1.00 |
| ▸ | MMP7 | P09237 | 1/20 | 1.00 |
| ▸ | MMP8 | P22894 | 1/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594373 | 1.00 | MMP9 (1.00) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL8341893 | 1.00 | MMP9 (1.00) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7429119 | 1.00 | MMP9 (1.00) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7594723 | 1.00 | MMP9 (1.00) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7429131 | 1.00 | MMP9 (1.00) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7594720 | 1.00 | MMP9 (1.00) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL13035001 | 0.92 | MMP9 (0.85) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7593382 | 0.91 | MMP9 (0.84) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7593375 | 0.91 | MMP9 (0.84) | MMP9MMP2MMP1MMP3MMP7 | |
| SCHEMBL7594936 | 0.90 | MMP9 (1.00) | MMP9MMP2MMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147101-B1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-11-20 | — | — | EP | claimed |
| US-11718877-B2 | Methods for use in the diagnosis of autoimmune diseases | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20220288086-A1 | TREATMENT FOR BACTERIAL INFECTION | VYOME THERAPEUTICS LIMITED (IN) | 2022-09-15 | — | — | US | disclosed |
| US-9296011-B2 | Prosthesis having varied concentration of beneficial agent | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296011-B2 | Prosthesis having varied concentration of beneficial agent | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150196692-A1 | MULTIPLE DRUG DELIVERY FROM A BALLOON AND A PROSTHESIS | ABBOTT LABORATORIES (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150112425-A1 | DELIVERY OF HIGHLY LIPOPHILIC AGENTS VIA MEDICAL DEVICES | ABBOTT LAB (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150112425-A1 | DELIVERY OF HIGHLY LIPOPHILIC AGENTS VIA MEDICAL DEVICES | ABBOTT LAB (US) | 2015-04-23 | — | — | US | disclosed |
| US-8956639-B2 | Multiple drug delivery from a balloon and prosthesis | ABBOTT LABORATORIES (US) | 2015-02-17 | — | — | US | disclosed |
| US-8956639-B2 | Multiple drug delivery from a balloon and prosthesis | ABBOTT LABORATORIES (US) | 2015-02-17 | — | — | US | disclosed |
| US-20070110280-A1 | Methods for Determining Coating Thickness of a Prosthesis | ABBOTT LABORATORIES | 2007-05-17 | — | — | US | disclosed |
| US-7208190-B2 | Method of loading beneficial agent to a prosthesis by fluid-jet application | ABBOTT LABORATORIES (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208190-B2 | Method of loading beneficial agent to a prosthesis by fluid-jet application | ABBOTT LABORATORIES (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070088255-A1 | METHOD OF TREATING VASCULAR DISEASE AT A BIFURCATED VESSEL USING A COATED BALLOON | TONER JOHN L | 2007-04-19 | — | — | US | disclosed |
| US-20070088255-A1 | METHOD OF TREATING VASCULAR DISEASE AT A BIFURCATED VESSEL USING A COATED BALLOON | TONER JOHN L | 2007-04-19 | — | — | US | disclosed |
| US-20070053953-A1 | Method of loading beneficial agent to a prosthesis by fluid-jet application | VERLEE DONALD | 2007-03-08 | — | — | US | disclosed |
| US-20070053953-A1 | Method of loading beneficial agent to a prosthesis by fluid-jet application | VERLEE DONALD | 2007-03-08 | — | — | US | disclosed |
| US-20070027523-A1 | Method of treating vascular disease at a bifurcated vessel using coated balloon | ABBOTT LABORATORIES | 2007-02-01 | — | — | US | disclosed |
| US-20070027523-A1 | Method of treating vascular disease at a bifurcated vessel using coated balloon | ABBOTT LABORATORIES | 2007-02-01 | — | — | US | disclosed |
| EP-1147101-B1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288086-A1 | TREATMENT FOR BACTERIAL INFECTION | ELANE, CFTR, TLR5 | MMP9 1320/4885MMP2 429/4885MMP1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.